CD34+ immunoselected cells for poor graft function following allogeneic BMT

Cytotherapy

Volumn 2, Issue 5, 2000, Pages 367-370

  Mohty, M ^a   Faucher, C ^a   Chabannon, C ^a   Vey, N ^a   Stoppa, A M ^a   Ladaique, P ^a   Novakovitch, G ^a   Olivero, S ^a   Bouabdallah, R ^a   Gastaut, J A ^a,b   Maraninchi, D ^a,b   Blaise, D ^a,b  

^a INSTITUT PAOLI CALMETTES   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Allogeneic transplantation; Full chimerism; Poor graft function

Indexed keywords

ANTIBIOTIC AGENT; BUSULFAN; CD34 ANTIGEN; CYCLOSPORIN; FLUDARABINE; GANCICLOVIR; IMTIX; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY; HISTOCOMPATIBILITY ANTIGEN; IMMUNOSUPPRESSIVE AGENT;

ACUTE LEUKEMIA; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ANEMIA; APHERESIS; ARTICLE; BACTERIAL INFECTION; BLOOD CELL COUNT; CASE REPORT; CEREBROVASCULAR SURGERY; CHIMERA; CYTOMEGALOVIRUS INFECTION; GRAFT FAILURE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; GRANULOCYTOPENIA; HUMAN; LEUKEMIA REMISSION; LEUKOCYTE TRANSFUSION; LYMPHOCYTE TRANSFUSION; MALE; MYELODYSPLASTIC SYNDROME; PSEUDOMONAS PUTIDA; SEPSIS; SUBDURAL HEMATOMA; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT OUTCOME; ACUTE LYMPHOCYTIC LEUKEMIA; ALLOTRANSPLANTATION; BIOLOGICAL THERAPY; BLOOD CELL; BLOOD DONOR; BONE MARROW TRANSPLANTATION; CHEMISTRY; GRAFT REJECTION; HISTOCOMPATIBILITY; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; SIBLING; TRANSPLANTATION;

ADULT; ANTIGENS, CD34; BLOOD CELLS; BLOOD DONORS; BONE MARROW TRANSPLANTATION; CASE REPORT; GRAFT REJECTION; HISTOCOMPATIBILITY ANTIGENS; HUMAN; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; SIBLINGS; TISSUE THERAPY; TRANSPLANTATION CHIMERA; TRANSPLANTATION, HOMOLOGOUS;

EID: 17744378174     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/146532400539260     Document Type: Article

References (9)

1. Use of recombinant human granulocyte-macrophage colony-stimulating factor in graft failure after bone marrow transplantation
2. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy
3. Accelerated erythroid repopulation with no stem-cell competition effect in children treated with recombinant human erythropoietin after allogeneic bone marrow transplantation
4. Clinical use of hematopoietic growth factors in allogeneic bone marrow transplantation
5. + progenitor cells from matched related donors
6. + selected allogeneic bone marrow transplantation (ABMT) followed after 2 months by prophylactic donor lymphocytes infusion (DLI) in high risk hematologic malignancies
7. The use of recombinant human granulocyte-macrophage colony stimulating factor for the treatment of delayed engraftment following high dose therapy and autologous hematopoietic stem cell transplantation for lymphoid malignancies
8. Allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation
9. Treatment of poor marrow graft function with allogeneic CD34+ cells immunoselected from G-CSF-mobilized peripheral blood progenitor cells of the marrow donor